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We have previously demonstrated the ability of the vaccine vectors based on replicon RNA of the Australian
flavivirus Kunjin (KUN) to induce protective antiviral and anticancer CD8 T-cell responses using murine
polyepitope as a model immunogen (I. Anraku, T. J. Harvey, R. Linedale, J. Gardner, D. Harrich, A. Suhrbier,
and A. A. Khromykh, J. Virol. 76:3791-3799, 2002). Here we showed that immunization of BALB/c mice with
KUN replicons encoding HIV-1 Gag antigen resulted in induction of both Gag-specific antibody and protective
Gag-specific CD8 T-cell responses. Two immunizations with KUNgag replicons in the form of virus-like
particles (VLPs) induced anti-Gag antibodies with titers of >1:10,000. Immunization with KUNgag replicons
delivered as plasmid DNA, naked RNA, or VLPs induced potent Gag-specific CD8 T-cell responses, with one
immunization of KUNgag VLPs inducing 4.5-fold-more CD8 T cells than the number induced after immu-
nization with recombinant vaccinia virus carrying the gag gene (rVVgag). Two immunizations with KUNgag
VLPs also provided significant protection against challenge with rVVgag. Importantly, KUN replicon VLP
vaccinations induced long-lasting immune responses with CD8 T cells able to secrete gamma interferon and
to mediate protection 6 to 10 months after immunization. These results illustrate the potential value of the
KUN replicon vectors for human immunodeficiency virus vaccine design.
A major requirement for an effective human immunodefi-
ciency virus (HIV) vaccine is the induction of potent, broad,
and durable anti-HIV CD8 T-cell immunity (11, 21, 28). Only
a few vaccine modalities that safely and effectively induce
CD8 T-cell responses in humans have emerged, and a sub-
stantial diversity of approaches are currently being tested in
preclinical models (9, 21, 28). Replicon-based vaccine vectors
derived from positive-strand RNA viruses have recently
emerged as potentially valuable systems for the development
of vaccines (17). Alphavirus-based replicon vaccines have been
shown to be capable of inducing potent antibody and CD8
T-cell responses in mice and monkeys (22, 34) and have been
applied to the design of HIV type 1 (HIV-1) vaccines (7, 39,
42).
Replicon vectors based on the flavivirus Kunjin (KUN) have
recently been developed in our laboratories (18, 19, 40, 41) and
show considerable potential for use as vaccine vectors for in-
duction of protective CD8 T-cell responses (3). KUN repli-
con vectors have several potentially valuable characteristics for
vaccine design. KUN replicons do not induce cytopathic ef-
fects, which allows immunogens to be expressed for extended
periods both in vitro and in vivo (19, 40, 41), thus potentially
generating long-lived immunity. Also, flaviviruses are not
known to recombine in nature, thus precluding generation of
potentially harmful recombinant viruses in KUN replicon-im-
munized individuals infected with other flaviviruses. Further-
more, the enzootic host of KUN virus appears to be mainly
birds, with infections in humans nearly always asymptomatic.
There is no preexisting immunity to KUN virus in the majority
of the world’s populations, except in northern parts of Austra-
lia and neighboring islands where KUN virus is endemic. KUN
replicon-based vaccines can be delivered in the following two
ways: (i) plasmid DNA carrying replicon cDNA, which in turn
produces functional replicon RNA in vivo from the cytomeg-
alovirus (CMV) promoter by cellular RNA polymerase II; or
(ii) replicon RNA, which is transcribed in vitro and delivered
either as naked RNA or packaged into virus-like particles
(VLPs) before delivery by infection with these VLPs. KUN
replicons are unable to generate infectious virus in vivo, and
the design of the heterologous packaging system for produc-
tion of KUN VLPs also precludes the generation of any infec-
tious recombinant viruses during VLP preparation (18, 40).
HIV particle assembly and budding are directed by the
pr55gag polyprotein, which is the precursor for the internal
structural proteins (matrix, capsid, nucleocapsid, and p6) of
the mature virion (6). HIV Gag proteins are relatively con-
served and the target of cross clade immunity (8, 26). Both
CD4 and CD8 T-cell immunity directed against Gag proteins
are believed to be important for protection (10, 15). Although
not believed to mediate protection, anti-Gag antibodies are
raised in HIV-infected individuals and by experimental vac-
cines containing Gag, where the antibody responses may be
viewed as one measure of vaccine performance (30). Here we
show that immunization with KUN replicons expressing the
complete HIV-1 gag gene induced potent Gag-specific CD8
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T-cell and antibody responses and protected mice from chal-
lenge with recombinant vaccinia virus expressing the gag gene.
MATERIALS AND METHODS
Plasmids. The RNA-based and DNA-based KUN replicon vectors
C20UbHDVrep and pKUNrep1, respectively (41), were used for construction of
plasmids containing the HIV-1 gag gene. Essentially, the complete HIV-1 gag
gene was amplified by PCR from the pBRDH2-neo plasmid (an HIV-1SF2/BH10
construct) (14) with primers gagBssHII-F (5-ACCATGGGCGCGAGCATCG
GTATTA-3) and gagBssHII-R (5-CTAAAGCGCGCCTTGTGACGAGGGG
TC-3). The PCR product was then digested with BssHII and inserted into the
AscI sites of the two KUN vectors to produce plasmids KUNgagRNA and
KUNgagDNA, respectively (Fig. 1).
DNA and RNA transfections and immunofluorescence. For DNA transfection,
BHK21 cells in 60-mm-diameter dishes or on glass coverslips were transfected
with 2 or 0.4 g of plasmid DNA, respectively, using Lipofectamine Plus trans-
fection reagent (Life Technologies, Melbourne, Australia), as described by the
manufacturer. RNA was transcribed in vitro from the XhoI-linearized KUN-
gagRNA plasmid DNA using SP6 RNA polymerase and electroporated into
BHK21 cells as described previously (19). Coverslips with transfected cells were
fixed in 4% paraformaldehyde 28 to 48 h posttransfection and assayed for
expression of KUN NS3 or E protein by indirect immunofluorescence (IIF) with
anti-NS3 or anti-E antibodies, respectively, as described previously (43).
Radioimmunoprecipitation assay (RIPA). To metabolically label proteins,
BHK21 cells electroporated with KUNgag RNA were seeded into a six-well
plate, and at 32 h postelectroporation, the cells were radiolabeled for 4 h with
100 Ci of [35S]methionine/cysteine in the presence of actinomycin D (Sigma,
Castle Hill, Australia). Tissue culture fluid was collected, and the cells were lysed
in lysis buffer (phosphate-buffered saline [PBS] containing 0.5% Nonidet P-40).
Samples were incubated with anti-pr55gag antibody (diluted 1:50) overnight at
4°C and then incubated for 1 h with 30 l of 10% protein A-Sepharose beads at
4°C. Pelleted Sepharose beads were washed three times with PBS, resuspended
in gel loading buffer, boiled for 5 min, and separated on a sodium dodecyl
sulfate–10% polyacrylamide gel.
Electron microscopy (EM). BHK21 cells electroporated with KUNgag RNA or
KUN vector RNA were seeded into a 60-mm-diameter dish, and the cells were
then harvested at 24 and 48 h after electroporation. The cells were collected in
PBS and fixed with 3% glutaraldehyde in 0.1 M sodium phosphate buffer, pH 7.4.
The samples were treated with 1% osmium tetroxide, dehydrated with acetone,
and embedded in Epon 612 resin as previously described (23). Sections collected
on grids were stained with uranyl acetate and lead citrate. All specimens were
examined on a JEOL 1010 transmission electron microscope at 80 kV.
Preparation of VLPs. VLPs were prepared essentially as described previously
except that 3  106 BHK21 cells were electroporated with 30 g of in vitro-
transcribed KUNgag RNA. At 32 h postelectroporation, the cells were
trypsinized, subjected to a second electroporation using in vitro-transcribed
noncytopathic Semliki Forest virus (SFV) replicon RNA containing the Leu713-
to-Pro codon substitution in the SFV nsP2 gene and encoding KUN structural
proteins (derivative of SFV-MEC105) (18) (details will be described elsewhere)
and incubated for 48 to 60 h before harvesting secreted VLPs. The titer of
infectious VLPs was determined by infection of Vero cells with 10-fold serial
dilutions of the VLPs and counting the number of NS3-positive cells by IIF
analysis at 30 to 40 h postinfection.
Immunization of mice. Female BALB/c (H-2d) mice (6 to 8 weeks old) were
supplied by the Animal Resources Centre (Perth, Western Australia). Mice were
immunized as follows. (i) KUNgag DNA (100 g) was diluted in 100 l of PBS
and injected intramuscularly (i.m.) into the quadriceps muscle of each hind leg
(50 l in each leg). (ii) In vitro-transcribed KUNgag RNA (30 g) was dis-
solved in 100 l of diethyl pyrocarbonate-treated PBS and injected i.m. (50 l
into each leg). (iii) KUNgag VLPs in Dulbecco modified Eagle medium contain-
ing 5% fetal calf serum was injected intraperitoneally (i.p.) at 106 infectious
units (IU) per mouse. (iv) A KUN VLP encoding the murine polyepitope
(KUNmptVLP) which contains four H-2d-restricted epitopes, YPHFMPTML
(YPH), RPQASGVYM (RPQ), TYQRTRALV (TYQ) and SYIPSAEKI (SYI)
(2) was injected as for method iii. (v) Recombinant vaccinia virus (WR TK)
carrying HIV-1 gag (rVVgag) (29) (2  107 PFU in 200 l of PBS) was injected
i.p.
HIV Gag protein determination. BHK cells (1.25  105 of 2  106) electro-
porated with 5 to 10 g of KUNgag RNA were seeded into each well of a 24-well
plate. Culture fluid and cell lysate samples were harvested at various time
intervals. The total volume of culture fluid (500 l) was clarified and stored at
4°C. For cell lysate, the cells were washed twice with PBS and lysed in 500 l of
PBS containing 0.5% Nonidet P-40 for 5 min at room temperature. Samples were
then vortexed, clarified, and stored at70°C. The level of pr55gag protein present
in the sample was then quantified by using an indirect CAp24 enzyme-linked
immunosorbent assay (ELISA) kit (Perkin-Elmer Life Sciences, Boston, Mass.).
The assay was performed as recommended by the manufacturer. The total
amount of cell-associated and secreted pr55gag protein produced per 106 initially
transfected cells was calculated by multiplying the amount of protein detected in
the total volume of samples obtained from 1.25 105 of initially transfected cells
by a factor of 8.
Detection of antibodies to HIV-1 Gag protein by indirect ELISA. Each well of
the 96-well plates was coated with 1 g of recombinant pr55gag protein (ex-
pressed as His-tagged protein in Escherichia coli and purified using a Ni-agarose
column) overnight at 4°C in antigen coating buffer (15 mM Na2CO3, 35 mM
NaHCO3 [pH 9.6]). The wells were then blocked by incubation with 50-l
portions of blocking buffer (PBS containing 0.25% gelatin and 0.1% Tween 20)
for 1 h at 37°C and washed three times with wash buffer (PBS containing 0.05%
Tween 20). Serum samples from immunized mice, diluted in blocking buffer,
were placed in the wells and incubated for 1 to 2 h at room temperature, and the
wells were washed three times. The secondary antibody, horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G diluted 1:2,000 in blocking
buffer, was placed in the wells and incubated for 30 min at room temperature.
After the wells were washed three times, bound conjugate was developed by
incubation with 50 l of K-blue tetramethylbenzidine substrate (Graphic Scien-
tific, Brisbane, Australia) for 10 min at room temperature in the dark or until the
color developed. The reaction was then stopped by the addition of 50 l of 2 M
H2SO4, and the absorbance readings (optical density at 450 nm) were deter-
mined using an ELISA plate reader.
KUN VLP neutralization assay. KUN VLPs (200 l) containing encapsidated
KUN vector replicon RNA (5  105 IU) were incubated for 1 h at 37°C with 20
l of three different serum samples from KUNgag VLP-immunized mice which
showed the highest titers of Gag antibodies by ELISA. VLPs were also incubated
under the same conditions with a KUN anti-E monoclonal antibody (1) and with
sera from naive mice as positive and negative controls for the assay, respectively.
The titer of VLPs in each neutralization reaction mixture was determined from
FIG. 1. DNA and RNA KUN replicon constructs carrying the HIV-1 gag gene. The DNA and RNA constructs are driven by the CMV and SP6
promoters, respectively. The constructs contain the following: (i) sequences required for KUN RNA replication (5 and 3 untranslated region
[UTR]); (ii) sequence coding for the first 20 amino acids of the KUN C protein (C20); (iii) sequence coding for the last 22 amino acids of the KUN
E protein (E22); and (iv) sequences coding for the nonstructural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (shown as NS1-NS5).
Constructs also contain either an SP6 or CMV promoter upstream of the KUN 5 UTR for in vitro or in vivo RNA transcription, respectively. The
antigenomic sequence of the hepatitis delta virus ribozyme (HDVr) and the polyadenylation signal from simian virus 40 (pA) have been inserted
downstream of the 3 UTR to ensure production of KUN replicon RNA molecules with precise 3 termini for efficient initiation of replication.
Ubiquitin is the mouse ubiquitin gene, and FMDV2A is autoprotease 2A of the foot-and-mouse disease virus.
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the number of NS3-positive Vero cells detected by IIF analysis after infection
with serial 10-fold dilutions of the neutralization reaction mixtures.
ELISPOT and chromium release assays. Epitope-specific CD8 T cells se-
creting gamma interferon (IFN-) were enumerated by an enzyme-linked im-
munospot (ELISPOT) assay using peptide epitopes (Mimotopes, Clayton, Aus-
tralia) as described previously (20). The statistical significance of the different
values found for the groups was determined using an unpaired Student’s t test.
51Chromium (51Cr) release assays were performed using splenocytes from mice
sacrificed 2 to 3 weeks postimmunization, and splenocytes were restimulated in
vitro for 6 days with irradiated lipopolysaccharide blasts (responder/stimulator
ratio of 20:1) sensitized with the AMQMLKETI peptide (25 g/ml for 1 h in 200
l of medium at 37°C, followed by two washes). The resulting effector popula-
tions were split, and equal numbers were used in duplicate experiments against
peptide-sensitized and unsensitized 51Cr-labeled P815 target cells at the indi-
cated effector/target ratios.
Vaccinia virus protection assay. Immunized and control groups of 6- to
8-week-old female BALB/c mice (Animal Resource Center, Perth, Australia)
were challenged with recombinant vaccinia virus (TK) carrying the HIV-1 gag
gene (rVVgag) (29) or with the control rVV encoding the murine polyepitope
(rVVcont) (17). At day 4 postinfection, both ovaries were removed, washed, and
homogenized in 1 ml of PBS using aluminum mesh. The ovary vaccinia virus
titers were then determined by plaque assay on confluent CV1 cells (3). The
significance of the differences between the virus titers in the experimental and
control groups was calculated using a nonparametric unpaired t test.
RESULTS
Expression and secretion of gag particles in cells transfected
with KUN replicon vectors. To determine that the KUN rep-
licon-encoding gag gene constructs were able to efficiently pro-
duce pr55gag protein, plasmid KUNgagDNA was transfected
into BHK21 cells and examined for expression of KUN NS3
protein and pr55gag protein by IIF analysis (data not shown).
IIF analysis of transfected cells with KUN anti-NS3 antibodies
or HIV-1 anti-pr55gag antibodies showed that 40% of cells
were strongly positive for both proteins 40 h after transfection
with DNA-based replicons (data not shown). In vitro-tran-
scribed KUNgag RNA was transfected into BHK21 cells by
electroporation and examined for KUN NS3 expression by IIF
analysis with anti-NS3 antibodies and for HIV-1 gag expression
and secretion by RIPA with anti-pr55gag antibody. IIF analysis
of RNA-electroporated cells demonstrated significantly
greater transfection efficiency compared to cells transfected
with the corresponding DNA-based replicon vector, i.e., 85
and 40%, respectively (data not shown). RIPA with anti-
pr55gag antibody showed efficient Gag expression in KUNgag
RNA-electroporated cells and its secretion into the culture
fluid (Fig. 2A). A decrease in the amount of Gag protein in
cells from 0.5 h to 4 h of the chase period (Fig. 2A, cell lysate
lanes), correlated with the appearance of secreted Gag in the
culture fluid 4 h after chase labeling (Fig. 2A, lane 2). The
amount of Gag protein present in cells and in the culture fluid
was quantitated using an indirect ELISA (Fig. 2B) with anti-
CAp24 antibody-coated microtiter plates (Perkin-Elmer Life
Sciences). Comparison with a purified p24 protein of known
concentration showed that the total amount of Gag protein
produced from 106 of initially transfected BHK cells 60 h after
electroporation of KUNgag RNA was equivalent to 632 ng of
CAp24 protein, with 410 ng detected in the cell lysates and 222
ng detected in the culture fluid.
To examine whether Gag protein was assembled into se-
creted particles, we performed EM analysis of transfected
cells. Characteristic 100- to 120-nm-diameter particles were
present in cells transfected with KUNgag RNA (Fig. 3A) but
not in cells transfected with the KUN vector replicon RNA
(Fig. 3B). In addition, the assembled gag particles were ob-
served to bud from the plasma membrane (Fig. 3C) and were
released into the extracellular medium (Fig. 3D). Taken to-
gether, the results of IIF, RIPA, ELISA, and EM analyses
demonstrate efficient expression of secreted gag particles in
cells transfected with KUN replicon vectors carrying the HIV-1
gag gene.
Induction of HIV-1 Gag-specific antibody responses. Sera
from mice immunized twice with KUNgag VLPs (106 IU per
mouse) or once with rVVgag (2  107 PFU per mouse) were
examined for the presence of antibodies to Gag. The antibody
responses were similar after immunization with KUNgag VLPs
and rVVgag (Fig. 4).
Absence of neutralizing antibody response to the KUN en-
velope protein after VLP immunizations. Effective booster im-
munization using a second inoculation with the same virus
vector-based vaccine usually demands that the primary immu-
nizations did not lead to induction of neutralizing antibodies
(36). To determine whether there was any significant neutral-
izing antibody response to the KUN envelope VLP protein
after two immunizations with KUNgag VLPs, a VLP infec-
tivity neutralization assay was performed. In the absence of
FIG. 2. Production and secretion of Gag protein. (A) Radiolabeled
culture fluid and cell lysate, collected 0.5 and 4 h after labeling with
[35S]methionine/cysteine from KUNgag-electroporated cells, was im-
munoprecipitated with anti-pr55gag antibody and separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. The migration of a
radiolabeled pr55gag protein in the gel is indicated by the arrow.
(B) Culture fluid and cell lysate were collected from KUNgag RNA-
electroporated cells at different time intervals, and the amount of
produced Gag protein was determined by using a Perkin-Elmer p24
ELISA kit. The total amount of cell-associated (cell lysate [black
circles]) and secreted (culture fluid [black squares]) pr55gag produced
per 106 initially transfected BHK cells at different times posttransfec-
tion was calculated as described in Materials and Methods.
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neutralizing antibodies, VLPs incubated with sera from na-
ive mice showed VLP titers of 2.1  106  3.8  105 IU/ml.
As expected, in the presence of a neutralizing antienvelope
monoclonal antibody, the VLP’s infectivity was completely
neutralized (data not shown). Sera from mice (n 	 3) im-
munized twice with KUNgag VLPs showed no significant
neutralizing activity, as the VLP titer was 6.3  105  1.3 
105 IU/ml.
Induction of HIV-1 Gag-specific CD8 T-cell responses.
HIV-1 Gag protein contains a H-2d-restricted CD8 T-cell
epitope, AMQMLKETI (AMQ), which was used as a peptide
to detect Gag-specific CD8 T-cell responses in immunized
BALB/c mice using the IFN- ELISPOT assay. BALB/c mice
were immunized once or twice with rrVVgag or KUN replicon
vaccines encoding Gag (KUNgag DNA, KUNgagRNA, and
KUNgag VLPs). Overall, KUNgag VLPs generated higher
CD8 T-cell responses than KUNgag RNA did, which gave
higher responses than KUNgag DNA, with responses from the
latter two modalities broadly comparable to that of rVVgag
(Fig. 5A). However, a single immunization with KUNgag VLPs
induced a 4.5-fold-greater response than one immunization
with rVVgag (KUNgag VLP versus rVVgag, P 	 0.012) (Fig.
5A).
Mice immunized twice with KUNgagRNA, KUNgag VLPs,
and rVVgag were also assayed for the induction of cytotoxic
T-cell responses by 51Cr release assay (Fig. 5B). Significant
cytotoxic activity specific for the AMQ epitope was observed
(Fig. 5B). The response induced by immunization with KUN-
gag VLPs was comparable to that observed in mice immunized
with rVVgag.
These data illustrate that KUN replicon-based vaccines can
efficiently induce Gag-specific CD8 T cells, generating re-
sponses greater or similar in magnitude to those induced by
recombinant vaccinia virus.
KUNgag RNA or KUNgag VLP immunization protects mice
from experimental viral challenge. To determine whether the
FIG. 3. EM of KUNgag RNA-transfected BHK21 cells. (A) 100- to 120-nm-diameter gag particles assembling and budding (indicated by arrows
and arrowheads, respectively) from internal cytoplasmic membranes. (B) Cells transfected with control KUN RNA. (C) gag particle (indicated by
arrow) budding from the plasma membrane (pm). (D) gag particle (indicated by arrow) secreted into the extracellular medium. Bars, 200 nm (A,
C, and D) and 500 nm (B).
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T-cell responses induced by immunization with KUNgag rep-
licon vectors can protect against viral challenge, groups of mice
were vaccinated twice with KUNgag VLP or a control VLP not
encoding Gag. The mice were then challenged with either
rVVgag or a control rVV not encoding Gag (rVVcont). Mice
immunized with KUNgag VLPs showed an average reduction
of 30-fold (P 	 0.0003) in rVVgag titers compared to mice
immunized with a control VLP (Fig. 6, top graph). In a parallel
experiment, the mice immunized with KUNgag VLP or control
VLPs were challenged with rVVcont, and no significant differ-
ence in ovary rVVcont titers was observed (P 	 0.9) (Fig. 6,
bottom graph). This illustrates that Gag-specific immunity was
responsible for the KUNgag VLP-mediated reduction in rV-
Vgag titers. The rVV titers in naive animals were not signifi-
cantly different from those of control VLP-immunized animals
in both experiments (data not shown). In a separate experi-
ment, two immunizations with 30 g of KUNgag RNA also
resulted in a95% reduction in ovary rVVgag titers (P	 0.01)
(data not shown).
Long-term CD8 T-cell responses elicited by KUN replicon
VLP vaccines. To analyze the long-term CD8 T-cell immunity
induced by KUN VLP vaccines, mice were immunized with a
single inoculation of KUNgag VLPs and the AMQ-specific
responses were analyzed by an ELISPOT assay after 2 weeks
and after 6 months. The responses at 6 months were not sig-
nificantly different from those seen at 2 weeks (P 	 0.75) (Fig.
7A), illustrating the induction of long-lasting CD8 T-cell re-
sponses by KUNgag VLP immunization. A similar long-term
maintenance of epitope-specific CD8 T cells capable of se-
creting IFN- was observed after immunization with a KUN
VLP encoding the murine polyepitope (KUNmptVLP), a vac-
cine encoding four H-2d-restricted CD8 T-cell epitopes. We
have previously published the responses to these four epitopes
2 to 3 weeks after immunization with KUNmptVLP (3), and
we now show that after 6 months these responses have not
significantly diminished (Fig. 7B), illustrating that long-term
maintenance of CD8 T-cell responses is not restricted to
AMQ-specific CD8 T cells. Furthermore, when mice, which
had been immunized with KUNmptVLP 10 months previously,
were challenged with a recombinant vaccinia virus encoding
the same four epitopes, substantial protection was still appar-
ent (Fig. 7C). KUNmptVLP-immunized mice showed an aver-
age reduction of 100-fold in ovary virus titers from that of
mock-immunized control mice (P 	 0.015).
DISCUSSION
We describe here the generation of KUN replicon vaccine
vectors carrying the complete HIV-1 gag gene and show that
they were able to produce secreted gag particles in vitro. Mice
immunized with KUNgag DNA, RNA, or VLPs induced sig-
nificant Gag-specific CD8 T-cell responses, with one immu-
nization of KUNgag VLP inducing 4.5-fold-more CD8 T cells
than those induced after immunization with rVVgag. KUNgag
VLP and RNA immunization also mediated substantial pro-
tection of mice against challenge with rVVgag. Importantly,
KUN VLP vaccines were able to induce enduring CD8 T cells
capable of secreting IFN- and mediating protection against
vaccinia virus challenge 6 to 10 months postimmunization.
These results significantly extend our previous data obtained
with murine polyepitope (3) and demonstrate the utility of
KUN-based vectors for HIV vaccine design.
The ability to induce HIV Gag-specific immune responses
effectively appears to depend on the vector’s ability to produce
Gag protein in the form of secreted, self-assembled gag parti-
cles (31). The assembly of secreted gag particles requires ex-
pression of Gag with the native amino-terminal glycine residue
(12). To achieve this, the HIV-1 gag gene was inserted into the
KUN replicon vector downstream of the mouse ubiquitin gene
(Fig. 1). Cleavage by cellular proteases at the carboxy terminus
of ubiquitin allows the release of Gag with native amino-ter-
minal glycine residue. In order to release the Gag protein from
the remaining Gag-KUN polyprotein, the foot-and-mouse dis-
ease virus 2A autoprotease sequence was inserted at the C
terminus of Gag (Fig. 1). The results of EM (Fig. 3) and of
RIPA (Fig. 2A) demonstrated that the Gag protein produced
from the KUN replicon RNA vector was correctly processed
and assembled into secreted gag particles. Quantitative analysis
of Gag expression, using a commercial anti-p24 ELISA kit, in
cells transfected with KUNgag RNA showed a high level of
total Gag expression of approximately 600 ng per 106 initially
transfected cells by 60 h posttransfection, with at least one-
third of the protein being secreted into the culture fluid (Fig. 2B).
These very high yields compared to other systems (14, 27, 31) are
FIG. 4. Anti-pr55gag antibody levels in mice after immunization
with KUNgag VLPs and rVVgag. Mice were immunized twice with 106
IU of KUNgag VLPs or control KUN VLPs or once with 2  107 PFU
of rVVgag. Two to three weeks after the last immunization, mouse sera
were analyzed for anti-pr55gag antibodies using an ELISA against pu-
rified recombinant pr55gag protein, as described in Materials and
Methods. Optical density at 450 nm (OD450) is shown on the y axis,
while the dilution of the serum sample is shown on the x axis.
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likely to reflect the ability of the transfected cells to divide within
the 60-h incubation period, with daughter cells retaining replicat-
ing KUNgag RNA and Gag protein production (41).
A major problem for efficient expression of native HIV
structural genes when plasmid DNA-based expression vectors
are used is the presence of multiple inhibitory sequences,
which are responsible for poor transport of mRNAs from the
nucleus to the cytoplasm (32, 35). The advantage of cytoplas-
mic virus-based vectors like KUN is that they do not require
modification of HIV inhibitory sequences to facilitate Gag,
FIG. 5. T-cell responses specific for the CD8 T-cell epitope AMQMLKETI (AMQ) induced by different delivery modalities of KUN replicons
carrying the HIV-1 gag gene or with recombinant vaccinia virus carrying the HIV-1 gag gene (rVVgag). (A) ELISPOT analysis of BALB/c mice
(four mice in each group) responses after immunization with the indicated vaccine modalities. Mice received a single immunization (white bars)
or two immunizations (2 weeks between the two immunizations) (black bars). (B) Standard 6-h 51Cr release assay using restimulated splenocytes
from BALB/c mice (four mice in each group) immunized twice with KUNgag RNA, KUNgag VLPs, or rVVgag. 51Cr-labeled target cells were
sensitized with (black squares) or without (white squares) AMQ peptide. Values are means  standard errors (SE). Control VLP, control KUN
VLPs not encoding Gag.
FIG. 6. Protection of BALB/c mice immunized with KUNgag VLPs against challenge with recombinant vaccinia virus carrying the gag gene.
Mice (10 mice in each group) were immunized i.p. twice with 106 KUNgag VLPs or the same dose of a control VLP not encoding Gag. The mice
were then challenged intravenously 14 days after the last vaccination with 5  106 PFU of rVVgag (top graph) or a control rVV not encoding Gag
(rVVcont) (bottom graph), and the ovary vaccinia virus titers on day 4 postchallenge were determined.
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Gag-Pol, and Env protein expression. This also appears to be
true for KUNgag DNA, since HIV Gag was efficiently ex-
pressed by KUNgag DNA transfected cells, as judged by CD8
T-cell induction (Fig. 5A). Only a few KUNgag replicon RNA
molecules probably need to escape from the nucleus into the
cytoplasm to establish a replicating pool of replicon RNA
capable of efficient protein production.
HIV-1 Gag has been used as the immunogen in a number of
murine studies evaluating different vaccine vectors (5, 13, 27,
30, 33, 39). For instance, three DNA immunizations that tar-
geted Gag to the secretory pathway (pSc-Gag) followed by a
rVVgag booster immunization was reported to induce 50
AMQ-specific IFN- spots/106 splenocytes at the peak of the
CD8 T-cell response on day 5 (31), whereas more than 150
AMQ-specific IFN- spots/106 splenocytes were seen after 3
weeks following a single immunization with KUNgag VLP (Fig.
5). After two immunizations with KUNgag VLPs, a challenge
with rVVgag resulted in an average reduction of 30-fold in
ovary vaccinia virus titers, a protective activity known to be
mediated by Gag-specific CD4 and CD8 T cells (24). These
results are broadly comparable with related studies measuring
protection against rVVgag in mice (31, 33, 39). However, com-
parisons are complicated by the use of (i) different schedules
and routes of immunization, (ii) vaccinia viruses with different
virulence characteristics, and (iii) different routes of vaccinia
virus challenge (31, 33, 39).
Two immunizations with KUNgag VLPs induced antibody
responses to the replicon-encoded Gag protein with end point
titers of approximately 1/10,000, similar to those reported for
mice immunized with 10 g of p55gag protein emulsified in the
highly effective MF59 oil-in-water adjuvant (30). In contrast,
the induction of neutralizing anti-KUN VLP vector antibodies
by KUN VLP vaccines appeared to be inefficient as evidenced
by (i) the ability to effectively boost KUNgag VLP-induced
responses with KUNgag VLPs (Fig. 5 and 6), and (ii) the
failure to detect significant levels of neutralizing antibodies to
the KUN envelope protein after two immunizations with
KUNgag VLPs (see Results). The latter is certainly not the
case after two immunizations with recombinant vaccinia vi-
ruses (4). Although the majority of the world’s populations
have no anti-KUN neutralizing antibodies, cross-reactive fla-
vivirus-specific CD8 T cells recognizing nonstructural pro-
teins may be widespread (38). However, current evidence sug-
gests that such preexisting anti-vector CD8 T-cell responses
need to be extremely high before they effectively interfere with
a vaccine vector’s ability to raise CD8 T-cell responses spe-
cific for the vaccine antigen (37).
Perhaps the most impressive outcome of KUN VLP immu-
nization is the maintenance for 6 to 10 months of CD8 T cells
that are capable of immediate IFN- secretion and of mediat-
ing protection within the 4 days of the rVV challenge assay
(Fig. 7). Such long-term maintenance of effector CD8 T cells
capable of immediate protective activities may emerge as an
important feature of effective vaccination against HIV, since
the postchallenge generation of new effectors from a vaccine-
induced memory CD8 T-cell pool may simply be too slow to
FIG. 7. Long-term immune responses elicited by KUN replicon VLP vaccines. (A) ELISPOT response to the AMQ epitope in BALB/c mice
(four mice in each group) 2 weeks and 6 months after a single immunization with 106 IU of KUNgag VLP. (B) ELISPOT analysis of splenocytes
from BALB/c mice (eight mice in each group) detected at 6 months after two immunizations (4 weeks between the two immunizations) with 106
IU of the KUN replicon VLPs encoding murine polyepitope immunogen (KUNmptVLP). CD8 T-cell responses are shown for individual epitopes
encoded by murine polyepitope, i.e., YPHFMPTML (YPH), RPQASGVYM (RPQ), TYQRTRALV (TYQ), and SYIPSAEKI (SYI). (C) BALB/c
mice (six mice in each group) were vaccinated twice with 106 IU of KUNmptVLP (4 weeks between the two immunizations), and 10 months after
the second immunization, mice were challenged with 106 PFU of recombinant vaccinia virus encoding murine polyepitope. Vaccinia virus titers
in ovaries were measured at day 4 after infection. All control mice were mock immunized with PBS. Values are means  standard errors (SE).
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deal effectively with the explosive retroviral infection (2, 16,
25). We are currently evaluating whether KUN vaccine’s
unique noncytopathic persistence in vivo is responsible for the
long-term maintenance of effector CD8 T cells.
ACKNOWLEDGMENTS
T. J. Harvey and I. Anraku contributed equally to the experimental
work and should be considered joint first authors. A. Suhrbier and
A. A. Khromykh contributed equally to the intellectual input and
planning and should be considered joint last authors.
This work was funded in part by grant RA21 AI48420-01 from the
National Institute of Health and grant 142911 from the National
Health and Medical Research Council of Australia.
We thank A. G. M. Bustra, University of Groningen, Groningen,
The Netherlands, for help with the project.
REFERENCES
1. Adams, S. C., A. K. Broom, L. M. Sammels, A. C. Hartnett, M. J. Howard,
R. J. Coelen, J. S. Mackenzie, and R. A. Hall. 1995. Glycosylation and
antigenic variation among Kunjin virus isolates. Virology 206:49–56.
2. Altes, H. K., D. A. Price, and V. A. Jansen. 2001. Effector cytotoxic T
lymphocyte numbers induced by vaccination should exceed levels in chronic
infection for protection from HIV. Vaccine 20:3–6.
3. Anraku, I., T. J. Harvey, R. Linedale, J. Gardner, D. Harrich, A. Suhrbier,
and A. A. Khromykh. 2002. Kunjin virus replicon vaccine vectors induce
protective CD8 T-cell immunity. J. Virol. 76:3791–3799.
4. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal
vaccination overcomes the barrier to recombinant vaccinia immunization
caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96:
4512–4517.
5. Bojak, A., J. Wild, H. Wolf, and R. Wagner. 2002. Efficiency of a myogenic
DNA vaccine is strictly dependent upon cellular localization of HIV-1
Pr55gag. Vaccine 20:1980–1984.
6. Coffin, J. M., S. H. Hughes, and H. E. Varmus (ed.). 1997. Retroviruses. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
7. Davis, N. L., A. West, E. Reap, G. MacDonald, M. Collier, S. Dryga, M.
Maughan, M. Connell, C. Walker, K. McGrath, C. Cecil, L. H. Ping, J.
Frelinger, R. Olmsted, P. Keith, R. Swanstrom, C. Williamson, P. Johnson,
D. Montefiori, and R. E. Johnston. 2002. Alphavirus replicon particles as
candidate HIV vaccines. IUBMB Life 53:209–211.
8. Durali, D., J. Morvan, F. Letourneur, D. Schmitt, N. Guegan, M. Dalod, S.
Saragosti, D. Sicard, J. P. Levy, and E. Gomard. 1998. Cross-reactions
between the cytotoxic T-lymphocyte responses of human immunodeficiency
virus-infected African and European patients. J. Virol. 72:3547–3553.
9. Edgeworth, R. L., J. H. San, J. A. Rosenzweig, N. L. Nguyen, J. D. Boyer, and
K. E. Ugen. 2002. Vaccine development against HIV-1: current perspectives
and future directions. Immunol. Res. 25:53–74.
10. Gandhi, R. T., and B. D. Walker. 2002. Immunologic control of HIV-1.
Annu. Rev. Med. 53:149–172.
11. Gandhi, R. T., and B. D. Walker. 2002. Promises and pitfalls in the recon-
stitution of immunity in patients who have HIV-1 infection. Curr. Opin.
Immunol. 14:487–494.
12. Gottlinger, H. G. 2001. The HIV-1 assembly machine. AIDS 15(Suppl.
5):S13–S20.
13. Haglund, K., I. Leiner, K. Kerksiek, L. Buonocore, E. Pamer, and J. K. Rose.
2002. High-level primary CD8 T-cell response to human immunodeficiency
virus type 1 Gag and Env generated by vaccination with recombinant vesic-
ular stomatitis viruses. J. Virol. 76:2730–2738.
14. Harrich, D., C. Hsu, E. Race, and R. B. Gaynor. 1994. Differential growth
kinetics are exhibited by human immunodeficiency virus type 1 TAR mu-
tants. J. Virol. 68:5899–5910.
15. Imami, N., A. Pires, G. Hardy, J. Wilson, B. Gazzard, and F. Gotch. 2002. A
balanced type 1/type 2 response is associated with long-term nonprogressive
human immunodeficiency virus type 1 infection. J. Virol. 76:9011–9023.
16. Kaul, R., S. L. Rowland-Jones, J. Kimani, T. Dong, H. B. Yang, P. Kiama, T.
Rostron, E. Njagi, J. J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A.
Plummer. 2001. Late seroconversion in HIV-resistant Nairobi prostitutes
despite pre-existing HIV-specific CD8 responses. J. Clin. Investig. 107:
341–349.
17. Khromykh, A. A. 2000. Replicon-based vectors of positive strand RNA
viruses. Curr. Opin. Mol. Ther. 2:555–569.
18. Khromykh, A. A., A. N. Varnavski, and E. G. Westaway. 1998. Encapsidation
of the flavivirus Kunjin replicon RNA by using a complementation system
providing Kunjin virus structural proteins in trans. J. Virol. 72:5967–5977.
19. Khromykh, A. A., and E. G. Westaway. 1997. Subgenomic replicons of the
flavivirus Kunjin: construction and applications. J. Virol. 71:1497–1505.
20. Le, T. T., D. Drane, J. Malliaros, J. C. Cox, L. Rothel, M. Pearse, T.
Woodberry, J. Gardner, and A. Suhrbier. 2001. Cytotoxic T cell polyepitope
vaccines delivered by ISCOMs. Vaccine 19:4669–4675.
21. Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for
vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol.
20:73–99.
22. Lundstrom, K. 2002. Alphavirus-based vaccines. Curr. Opin. Mol. Ther.
4:28–34.
23. Mackenzie, J. M., M. K. Jones, and P. R. Young. 1996. Improved membrane
preservation of flavivirus-infected cells with cryosectioning. J. Virol. Meth-
ods 56:67–75.
24. Mata, M., Z. J. Yao, A. Zubair, K. Syres, and Y. Paterson. 2001. Evaluation
of a recombinant Listeria monocytogenes expressing an HIV protein that
protects mice against viral challenge. Vaccine 19:1435–1445.
25. Mateo, L., J. Gardner, and A. Suhrbier. 2001. Delayed emergence of bovine
leukemia virus following vaccination with a protective cytotoxic T cell-based
vaccine. AIDS Res. Hum. Retrovir. 17:1447–1453.
26. McAdam, S., P. Kaleebu, P. Krausa, P. Goulder, N. French, B. Collin, T.
Blanchard, J. Whitworth, A. McMichael, and F. Gotch. 1998. Cross-clade
recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS
12:571–579.
27. McGettigan, J. P., S. Sarma, J. M. Orenstein, R. J. Pomerantz, and M. J.
Schnell. 2001. Expression and immunogenicity of human immunodeficiency
virus type 1 Gag expressed by a replication-competent rhabdovirus-based
vaccine vector. J. Virol. 75:8724–8732.
28. McMichael, A. J., and S. L. Rowland-Jones. 2001. Cellular immune re-
sponses to HIV. Nature 410:980–987.
29. Nixon, D. F., A. R. Townsend, J. G. Elvin, C. R. Rizza, J. Gallwey, and A. J.
McMichael. 1988. HIV-1 gag-specific cytotoxic T lymphocytes defined with
recombinant vaccinia virus and synthetic peptides. Nature 336:484–487.
30. O’Hagan, D., M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and
G. Ott. 2002. Synergistic adjuvant activity of immunostimulatory DNA and
oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine
20:3389–3398.
31. Qiu, J. T., B. Liu, C. Tian, G. N. Pavlakis, and X. F. Yu. 2000. Enhancement
of primary and secondary cellular immune responses against human immu-
nodeficiency virus type 1 Gag by using DNA expression vectors that target
Gag antigen to the secretory pathway. J. Virol. 74:5997–6005.
32. Qiu, J. T., R. Song, M. Dettenhofer, C. Tian, T. August, B. K. Felber, G. N.
Pavlakis, and X. F. Yu. 1999. Evaluation of novel human immunodeficiency
virus type 1 Gag DNA vaccines for protein expression in mammalian cells
and induction of immune responses. J. Virol. 73:9145–9152.
33. Rayevskaya, M. V., and F. R. Frankel. 2001. Systemic immunity and mucosal
immunity are induced against human immunodeficiency virus Gag protein in
mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol.
75:2786–2791.
34. Schlesinger, S. 2001. Alphavirus vectors: development and potential thera-
peutic applications. Expert Opin. Biol. Ther. 1:177–191.
35. Schneider, R., M. Campbell, G. Nasioulas, B. K. Felber, and G. N. Pavlakis.
1997. Inactivation of the human immunodeficiency virus type 1 inhibitory
elements allows Rev-independent expression of Gag and Gag/protease and
particle formation. J. Virol. 71:4892–4903.
36. Sharpe, S., N. Polyanskaya, M. Dennis, G. Sutter, T. Hanke, V. Erfle, V.
Hirsch, and M. Cranage. 2001. Induction of simian immunodeficiency virus
(SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia
virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector
immunity. J. Gen. Virol. 82:2215–2223.
37. Sherritt, M. A., J. Gardner, S. L. Elliott, C. Schmidt, D. Purdie, G. Deliy-
annis, W. R. Heath, and A. Suhrbier. 2000. Effect of pre-existing cytotoxic T
lymphocytes on therapeutic vaccines. Eur. J. Immunol. 30:671–677.
38. Spaulding, A. C., I. Kurane, F. A. Ennis, and A. L. Rothman. 1999. Analysis
of murine CD8 T-cell clones specific for the dengue virus NS3 protein:
flavivirus cross-reactivity and influence of infecting serotype. J. Virol. 73:
398–403.
39. Vajdy, M., J. Gardner, J. Neidleman, L. Cuadra, C. Greer, S. Perri, D.
O’Hagan, and J. M. Polo. 2001. Human immunodeficiency virus type 1
Gag-specific vaginal immunity and protection after local immunizations with
Sindbis virus-based replicon particles. J. Infect. Dis. 184:1613–1616.
40. Varnavski, A. N., and A. A. Khromykh. 1999. Noncytopathic flavivirus rep-
licon RNA-based system for expression and delivery of heterologous genes.
Virology 255:366–375.
41. Varnavski, A. N., P. R. Young, and A. A. Khromykh. 2000. Stable high-level
expression of heterologous genes in vitro and in vivo by noncytopathic
DNA-based Kunjin virus replicon vectors. J. Virol. 74:4394–4403.
42. Villacres, M. C., J. Zuo, and C. C. Bergmann. 2000. Maintenance of CD8
T-cell memory following infection with recombinant sindbis and vaccinia
viruses. Virology 270:54–64.
43. Westaway, E. G., J. M. Mackenzie, M. T. Kenney, M. K. Jones, and A. A.
Khromykh. 1997. Ultrastructure of Kunjin virus-infected cells: colocalization
of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in
virus-induced membrane structures. J. Virol. 71:6650–6661.
VOL. 77, 2003 KUN VIRUS REPLICON VECTORS FOR HIV VACCINE DEVELOPMENT 7803
 o
n
 Septem
ber 15, 2016 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
